Details for Patent: 9,242,986

✉ Email this page to a colleague

Patent 9,242,986 protects TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ, and is included in six NDAs.

Protection for TIVICAY PD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in fourteen countries.

Patent landscape, scope, and claims:

Title:	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Abstract:	A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##
Inventor(s):	Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP)
Assignee:	SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:	14/272,823
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,242,986
Patent Claim Types: see list of patent claims	Compound;
More… ↓ ⤷ Subscribe

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	TIVICAY PD	dolutegravir sodium	TABLET, FOR SUSPENSION;ORAL	213983-001	Jun 12, 2020		RX	Yes	Yes	9,242,986*PED	⤷ Subscribe			Y		⤷ Subscribe
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	9,242,986*PED	⤷ Subscribe			Y		⤷ Subscribe
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes	9,242,986*PED	⤷ Subscribe			Y		⤷ Subscribe
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes	9,242,986*PED	⤷ Subscribe			Y		⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009325128	⤷ Subscribe
Australia	2014277831	⤷ Subscribe
Brazil	PI0923217	⤷ Subscribe
Canada	2744019	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration